One Two
Sie sind hier: Startseite Teams Henrichfreise lab

Henrichfreise lab

 

Research focus

 

Peptidoglycan biosynthesis in cell wall-lacking bacteria

For the obligate intracellular Chlamydiaceae, there is no need to resist osmotic challenges. Thus the genomically-reduced pathogens lack a cell wall. Nevertheless, Chlamydiaceae synthesize peptidoglycan at certain locations and times during their biphasic life cycle to control immune modulation and to support cell division. During the unusual process of chlamydial cell division asymmetric cell poles mature into two equally sized daughter cells separated by a septum which contains a short-lived peptidoglycan ring. Moreover, the cell wall-targeting penicillin does not kill Chlamydiaceae but blocks cell division and induces reversible persistence. The underlying mechanisms of these phenomena are not fully understood.

We use Chlamydiaceae as a model system to explore how a minimal and modified cell wall biosynthesis machinery supports prokaryotic cell division. Moreover, we study the effects of (cell wall) antibiotics on chlamydial cell biology.

 Henrichfreise research 0

 

Research examples

 

Chlamydial AmiA is a novel penicillin target enzyme with dual activity

Henrichfreise research 1
 

 

Chlamydial GlyA serves as a source of D-alanine

Henrichfreise research 2

 

Spacial organization of the peptidoglycan biosynthesis machinery


Henrichfreise research 3


 

Functional conservation of  the peptidoglycan precursor lipid II pathway


Henrichfreise research 4

 

 

 

Team members

 

BeateHenrichfreise.jpgBeate Henrichfreise
Group Leader

Beate Henrichfreise studied biology and gained her PhD on antibiotic multi-resistance in Pseudomonas aeruginosa in 2006. In parallel to her PhD, she worked with Antiinfectives Intelligence, a service provider specialized in antiinfectives. Following a postdoctoral training at the Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, she joined industry in 2009 to gain experience in biotech and pharma industry working on peptides for technical and antimicrobial applications. Until 2012 she worked 50% at Novozymes A/S, Denmark at the Departments for Anti-Infective Discovery, Pharma Discovery and Peptide & Cell Discovery in the course of Marie Curie Actions and 50% at University Hospital Bonn to establish in parallel her independent field of basic research on cellular functions of peptidoglycan biosynthesis in cell wall lacking Chlamydiaceae. Returning to Germany for good in 2012, she attracted funding for a junior research group from the intramural funding scheme of the Medical Faculty of Bonn. In 2015 she became group leader at the inter-faculty Institute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn.

room 15
phone: +49(0)228 73 4637

e-mail

 

 

Iris LöckenerIris Löckener
PhD student

room 21
phone: +49(0)228 73 5269

e-mail

 

 

SebastianKrannich.jpgSebastian Krannich
PhD student

room 21
phone: +49(0)228 73 5269

e-mail

 

 

 

   

 

Julia HeymuthJulia Dannenberg
PhD student

room 21
phone: +49(0)228 73 5269

e-mail

 

 

Jenny Petrjukweb.jpgJenny Petrjuk
Scientific Associate

 

room:
phone:

e-mail

 

 



room

phone:

e-mail

 

 

 

 

 

 

 

 

 

 

Funding

 

  • DFG TRR261 Antibiotic CellMAP - Cellular mechanisms of antibiotic action and production, project A07: Mechanisms of ß-lactam induced persistence in chlamydiae,
  • Collaborative Research Grant, Emory University and University of Bonn, co-applicant
  • FEMHABIL, Medical Faculty, University of Bonn
  • DFG: Characterization of the chlamydial machinery for peptidoglycan remodelling
  • Maria von Linden program, University of Bonn
  • BONFOR, Medical Faculty, University of Bonn: The chlamydial anomaly: processing and recycling of the cell wall building block lipid II in cell wall-lacking bacteria
  • Fonds der chemischen Industrie e.V.: “Sachkostenzuschuss für den Hochschullehrernachwuchs”

 

Artikelaktionen